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Objective. The study aimed to assess the impact of HPV immunization campaigns organizational aspects, the characteristics of
immunization program (vaccination targets and type of offer), and communicative strategies adopted by four Italian administrative
regions on vaccination coverage observed.Methods. FromNovember 2017 toMarch 2018, regional and Local Health Units (LHUs)
representatives were invited to complete an online survey including 54 questions evaluating vaccination invite systems, access
systems to vaccination centres, reminder and recall systems, and adverse events surveillance. An overall descriptive analysis was
conducted. Since observed vaccine coverage (VC) obtained in females (2002-2004 birth cohorts) was lower than objectives fixed
by the Italian Ministry of Health, variables were assessed using the national VC mean obtained in the 2003 girls birth cohort as
outcome. Results. Twenty-six LHUs belonging to 4 Northern and Southern Italian regions participated in the study. Organizational
aspects significantly related to VC lower than the national mean were access to vaccine centres without appointment and parents’
reservation as appointment planning system. Recall systems for both the first and the second dose, including the appointment
in the invitation letter, the availability of regional immunization registry, and education of healthcare workers on universal HPV
immunization strategies, instead, were related to higher VC. As regards preadolescent immunization strategies, both VC obtained
in girls and boys were far from the Ministerial goals. Only 20% of LHUs introduced multicohort female strategies while all LHUs
adopted copayment targeting both men and women. Immunizations strategies targeting subjects at risk were implemented only
in half of participating LHUs. Conclusions. VC observed in participating LHUs are largely lower than the national objectives in all
anti-HPV vaccine targets. Both organizational and educational strategies have to be implemented to improve the VC goals.
1. Introduction
Human papillomavirus (HPV) is considered one of the
most common sexually transmitted infections in the world,
affecting people especially in developed countries. About
70-80% of the sexually active women and men will
acquire an HPV infection during their life [1]. Since HPV
was discovered to cause cervical, penile, anal, vaginal,
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oropharynx, hypopharynx, and larynx cancers, the develop-
ment of effective anti-HPV vaccines was considered one of
the most important public health goals to be achieved [2–4].
In 2006, the EuropeanMedicinesAgency (EMEA) approved a
quadrivalent vaccine containing antigens against four HPV-
types (6, 11, 16, and 18) and, one year later, they approved a
second bivalent vaccine against oncogenicHPV-types (16 and
18). Finally, in 2015, a nonavalent vaccine extending antigens
to five additional HPV-types (31, 33, 45, 52, and 58) to that
contained in the quadrivalent vaccine was approved by EMA
[5, 6].
Initially, HPV vaccination has been recommended for
adolescent women prior to sexual debut, and it has already
been showed to be highly effective in reducing HPV-related
lesions, such as genital warts as well asCervical Intraepithelial
Neoplasia (CIN) [7]. Increasing evidence demonstrated the
consistent burden of HPV-related diseases also in men, such
as anal, head, and neck cancers (4 times ormore thanwomen)
and penile cancers [8, 9].
Nowadays USA, Canada, Australia, and over 37 out of 53
European (EU) countries have introduced the vaccine into
their national routine immunization schedules and several of
these both for males and females [10].
In 2014, HPV vaccination coverage in the EU Region
accounted for about 50% in the primary target, while African
countries reported a mean 88% HPV vaccination coverage
(VC) [11]. In Italy, HPV vaccination is free and has been
actively offered to all girls during their 12th year of life
since 2007, and recently the National Vaccination Plan
(PNPV) 2017-2019 established a target vaccination coverage
of 95%, within three years of the start of the campaigns
[12]. However, despite several promotional activities, VC
is largely unsatisfactory, ranging from 30% to 75% among
Italian administrative regions for full HPV vaccination in
primary cohorts (birth cohort: 2005) of women and from 0%
to 65% among primary cohorts of men [13].
In Europe, several studies have previously indicated that
common reasons for not receiving or completing the HPV
vaccine were the perception of low risk or not needing
the vaccine, low perception of HPV vaccination benefits,
doubt about the safety and efficacy of the vaccines, fear of
side effects, low participation at school seminar on HPV
for school-based immunization campaign, lack of physician
recommendations, and cost of the vaccine [14–17].
Organizational aspects to improve HPV vaccine uptake
were also investigated, in particular the implementation of
immunization services’ accessibility, the role of reminder
systems, and communication technologies. Nevertheless,
previous evaluations were rarely comprehensive or specific,
thus compromising the estimate of the effect of interventions’
interaction and the consideration of HPV vaccine peculiari-
ties (i.e., the variety of involved targets and healthcare profes-
sionals, the role of parents, and the range and seriousness of
HPV-related diseases, including cancers) [18–29].
Aim of the present study was assessing the different
HPV immunization campaigns carried out in four Italian
administrative regions, evaluating the impact of organiza-
tional aspects, the characteristics of immunization program
(vaccination targets, e.g., female, male, categories at risk such
as men who have sex with men, etc., and type of offer),
and communicative strategies adopted by the regions on
vaccination coverage observed.
2. Material and Methods
An online questionnaire was administered through Google
Drive platform to 26 Local Health Units (LHUs), belonging
to 4 Northern and Southern Italian regions, where the
universal preadolescents HPV vaccine recommendation was
introduced before the PNPV2017-2019, covering 25.7%of the
national population.
From November 2017 to March 2018, regional and LHUs
representatives were invited to complete an online survey
including 54 questions evaluating HPV immunization poli-
cies targeting preadolescents, adults and subjects at risk,
obtained results in different targets, communication and
education strategies, and organizational characteristics of
vaccination centres. In particular, vaccination invite systems,
subjects who invites preadolescents, sending information
with invitation letter, subjects who administers the vaccine,
access system to vaccination centres, appointment planning
system, reminder of the first dose appointment, specific HPV
vaccine sessions, recall of subjects who missed the first and
the second dose, second dose appointment planning, and AE
surveillance within 30 minutes and since the day after were
investigated. An overall descriptive analysis was conducted.
Since observed VC obtained in females 2002-2004 birth
cohorts were lower than the objectives fixed by the Ministry
of Health, VC national mean was used as outcome. In
particular, the possible association of organizational aspects
with VC obtained in the female 2003 birth cohort higher
than the national mean (64.7%) [13] was tested through
univariable logistic regression.
VC obtained in boys were not considered as outcome
since the objectives fixed by the Ministry of Health in PNPV
2017-2019 refer to the 2006 birth cohort for which data were
not available.
After the collinearity assessment, factors resulting statis-
tically significant in univariable comparisons (p < 0.05) were
included in a multivariable model, by means of a stepwise
backward procedure.
Statistical analyses were conducted by the JMP software,
version 13.
2.1. Ethical Approval. Thestudy protocol was approved by the
Regional Ethic Committee of the Liguria region, Italy (P.R.
162REG2017).
3. Results
3.1. Universal Preadolescents HPVVaccination Organizational
Aspects. The main results concerning universal preadoles-
cents HPV vaccination organizational aspects are shown in
Table 1. Almost all LHUs invite preadolescents through letters
addressed to parents, which in 76.9% of cases included also
informative material. Schools are involved only in 26.9%
of cases. The access system to vaccination centre for the
first dose administration was by appointment in almost all
BioMed Research International 3
Table 1: Universal pre-adolescents HPV vaccination organizational
aspects.
Organizational aspects (N=26)
N (%)
Vaccination invite system
Letter addressed to parents by LHUs 25 (96.2%)
Information given at school 7 (26.9%)
SMS to parents 1 (3.8%)
Smartphone Application 1 (3.8%)
Subject who invites pre-adolescents
Healthcare workers of immunization centres 26 (100%)
Sending information with invitation letter 20 (76.9%)
Subjects who administers the vaccine
Healthcare workers of immunization centres 26 (100%)
Access system to vaccination centres
Free access 5 (19.2%)
Appointment 25 (96.1%)
Appointment planning system
Included in the invitation letter 19 (76%)
Parents reservation 10 (38.5%)
Reminder of the first dose appointment 14 (53.4%)
Specific HPV vaccine sessions 21 (80.8%)
Recall of subjects who missed the first dose 18 (69.2%)
Letter 14 (77.8%)
Phone call 9 (50.0%)
SMS 1 (5.9%)
Second dose appointment planning
During the first dose appointment 21 (80.8%)
Invitation letter 4 (15.4%)
Parents reservation 1 (3.8%)
Recall of subjects missing the second dose 16 (61.5%)
Phone call 8 (50%)
Invitation letter 10 (62.5%)
SMS 1 (6.3%)
AE surveillance within 30 minutes 21 (80.8%)
AE surveillance since the day after
Parents contact to immunization centre 17 (65.4%)
Report 9 (34.6%)
Regional vaccine-vigilance system 21 (80.8%)
LHU=Local Health Unit; SMS=Short Message Service; AE=Adverse Event
LHUs, and the appointment was included in the invitation
letter in 76% of cases. The second dose appointment was
planned during the first appointment in 80.8% of cases.
Only about half of the LHUs adopt reminder systems for
the first dose appointment. HPV vaccine is administered
in specific vaccine sessions in 80.8% of LHUs and recall
systems for subjects who missed the first and the second
dose are used in 69.2% and 61.5% of cases, respectively. As
regards adverse events surveillance after the HPV vaccine
administration, about 20% of LHUs reported no surveillance
within 30 minutes and no active regional vaccine-vigilance
system.
3.2. Immunization Strategies and Vaccine Coverage. As
regards preadolescent immunization strategies, both VC
obtained in boys and girls are largely suboptimal in partici-
pating LHUs and very far from the goals set by the Ministry
of Health in the PNPV 2012-2014 and 2017-2019 (Figures
1(a) and 1(b)). In particular, median VC for complete cycle
obtained in 2002, 2003, and 2004 girls birth cohorts were
67.7% (25-75p=59.7%-75.9%), 66.5% (25-75p=57%-77.5%),
and 66.5% (25-75p=51.4%-73.1%), respectively. In boys the
VC for complete cycle were 26.8% (25-75p=16.3%-45.8%) and
49.7% (25-75p=59.7%-75.9%) in 2003 and 2004 birth cohorts,
respectively.
Furthermore, only about 20% of LHUs introduced multi-
cohort female strategies while all adopted copayment target-
ing both men and women.
Immunizations strategies targeting subjects at risk are
implemented only in half of participating LHUs and a multi-
disciplinary network to identify them is active in 27%of cases.
The healthcare workers who recommend the HPV vaccine
are various but low in numbers (immunization centres,
gynaecologists, infectious diseases specialists, and general
practitioners in 41.7%, 25%, 33.4%, and 25%, respectively),
while the administration of HPV vaccine is centralized in
vaccine centres.
As regards vaccine registries, they are digitized in all
participating LHUs but only about the half of them are
present on a regional level.
3.3. Communication Strategies. Communication tools were
also investigated (Table 2). In particular, informative material
available at the immunization centres is prepared locally
in the majority of cases and translated in other languages
than Italian only in 19.2% of cases. A call centre to discuss
about vaccines is active in 53.8% of cases, formative moments
such as focus group addressed to preadolescents parents
were conducted in 42.3% of cases, and local media were
involved in informative campaigns in about 35% of LHUs.
The education of healthcare workers on universal strategy
was multidisciplinary and it was conducted in almost all the
LHUs.The analysis of suboptimal obtainedVC and of vaccine
hesitancy determinants was conducted only in 57.7% and
34.6% of cases, respectively.
Table 3 shows the results of univariable logistic regression
investigating the possible association between organizational
aspects and VC obtained in the female 2003-birth cohort.
Organizational aspects significantly related to VC lower than
the national mean were access to vaccine centres without
appointment and parents’ reservation as appointment plan-
ning system.
Recall systems for both the first and the second dose,
including the appointment in the invitation letter, the avail-
ability of regional immunization registry, and education of
healthcare workers on universal HPV immunization strate-
gies, instead, were related to higher VC.
After multivariable analysis, one variable resulted statis-
tically significant: access without appointment to vaccination
centres (p=0.038); recall systems resulted borderline, with
p=0.063 (Table 4). In particular, the probability to obtain VC
higher than the national mean is equal to 87.6% if a recall of
4 BioMed Research International
100
Cohort 2002
- ﬁrst dose
Cohort 2002
- complete
cycle
- complete
cycle
- complete
cycle
Cohort 2003-
ﬁrst dose
75p 25p Median
Cohort 2003 Cohort 2004
- ﬁrst dose
Cohort 2004
Girls
PNPV 2012-2014
PNPV 2012-2014
PNPV 2017-2019
95
90
85
80
75
70
65
60
55
50
VC
%
(a)
Cohort 2003
- ﬁrst dose
Cohort 2003
- complete
cycle
- complete
cycle
- complete
Cohort 2004-
ﬁrst dose
75p 25p Median
Cohort 2004 Cohort 2005
- ﬁrst dose
Cohort 2005
Boys
75
VC
%
70
65
60
55
50
45
40
35
30
25
20
15
10
＝Ｓ＝Ｆ？∗
∗
∗Ｊ；ＬＮＣ；Ｆ ＞；Ｎ；
(b)
Figure 1: Vaccine coverage (median, 25-75 p) for first dose and complete cycle obtained in preadolescents girls (birth cohorts 2002-2004)
(a) and boys (birth cohorts 2003-2005) (b) in participating Local Health Units and vaccine coverage objectives set by the Italian Ministry of
Health.
Table 2: Communication strategies about HPV vaccine.
Communication strategies (N=26)
N (%)
Informative material available at immunization centres
Ministry of Health 2 (7.7%)
Region 11(42.3%)
LHUs 13(50%)
Scientific agencies 3(11.5%)
Pharmaceutical companies 8(30.8%)
Translation of informative material 5(19.2%)
Call center 14(53.8%)
Focus group 11(42.3%)
Media 9(34.6%)
Education of HCWs on “universal” strategy 24(92.3%)
Immunization centres 16(66.7%)
General practitioners/Pediatricians 14(58.3%)
Gynecologists 9(37.5%)
Screening centres 9(37.5%)
Periodically 12(50%)
Discussion of obtained vaccine coverages 15(57.7%)
Analysis of vaccine hesitancy determinants 9(34.6%)
subjects missing the second dose is active. If the access system
to vaccine centre is without appointment, the probability
to obtain VC higher than the national mean is only 8.7%.
The two organizational aspects are related to a probability of
gaining higher VC of about 37%.
4. Discussion
This survey allowed us to obtain a detailed picture of a wide
range of HPV vaccine offer and promotion strategies and to
identify actions adopted in Italian LHUs that are associated
with VC higher than the national mean.
In our knowledge, the most studied strategies aimed
at gaining adequate HPV VC deal with the evaluation of
knowledge, attitudes, and determinants of acceptance and
refusal, and they mainly focus on preadolescents girls and
their parents [30–41].
Nevertheless, immunization strategies and organizational
aspects of vaccine centres also have a relevant role in deter-
mining the vaccine compliance.
Some studies investigated interventions to improve HPV
vaccine uptake but each of themwas evaluated separately [18–
23]. Other studies and recommendations on factors influenc-
ing VC integrated the evaluation of many interventions but
rarely specific for HPV vaccine, that is critical for the variety
of targets and healthcare professionals implicated in vaccine
counselling, the involvement of parents, and the relevance
of indications including cancers [24–27]. In particular, the
Community Preventive Services Task Force (CPSTF) sup-
ported by the Centers for Disease Control and Prevention
(CDC) provides evidence-based findings and recommenda-
tions on intervention approaches for increasing vaccination,
based on available scientific evidences [28]. Findings are
divided into three categories [29], including recommended
with strong evidence strategies aiming at enhancing access to
vaccination services (e.g., home visits, vaccination programs
in schools and organized child care centres, and vaccina-
tion programs in women, infants, and children settings),
increasing community demand for vaccinations (e.g., client
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Table 3: Univariable logistic regression of universal pre-adolescents HPV-vaccination vaccination organizational aspects associated with
gaining by LHU of vaccine coverage in 2003 girls birth cohort higher than the national mean.
Organizational aspects and communication strategies
Cohort 2003
LHU VC> National mean VC (64.7%)
Yes No P-value OR (95% C.I.)
Access system to vaccination centres
Free access 1 (5.9%) 4 (44.4%) 0.018 0.08 (0.01-0.87)
Recall of subjects who missed the first dose 14 (82.4%) 4 (44.4%) 0.046 5.8 (1-35.7)
Recall of subjects missing the second dose 13 (76.5%) 3 (33.3%) 0.032 6.5 (1.09-38.63)
Appointment planning system
Included in the invitation letter 15 (88.2%) 4 (44.4%) 0.017 9.37 (1.3-67.65)
Parents reservation 1 (5.9%) 4 (44.4%) 0.018 0.08 (0.01-0.87)
Immunization registry
Regional 12 (70.6%) 2 (22.2%) 0.019 8.4 (1.27-55.39)
Education of HCWs on “universal” strategy 17 (100%) 7 (77.8%) 0.043 NA
LHU=Local Health Unit; VC=Vaccine Coverage; HCW=Health Care Worker
Table 4: Organizational aspects selected by multivariate stepwise
logistic regression for prediction of gaining by LHU of vaccine
coverage in 2003 girls birth cohort higher than the national mean.
Organizational aspects
Recall of subjects missing the
second dose (p=0.063)
Yes No
Free access to vaccination
centres (p=0.038)
Yes 36.9% 8.7%
No 87.6% 53.4%
reminder and recall system and vaccination requirements for
child care, school, and college attendance), and provider- or
system-based interventions (e.g., immunization information
systems, provider assessment and feedback, and provider
reminders).
Among the abovementioned interventions, the active
invitation of eligible subjects represents one of the more
effective interventions to increase the VC. In this context,
almost all participating LHUs invite adolescents’ parents
by letter and adopt the appointment as access system to
vaccination centres, limiting the free access to 19.2% of cases.
In particular, the appointment is included in the invitation
letter in 76% of cases.
On the contrary, the access to vaccine centres without
appointment and parents’ reservation as appointment plan-
ning system are significantly related to VC lower than the
national mean. Further, recall systems for both the first and
the second dose is adopted only in 69.2% and 61.5% of
cases, even if recommendedwith strong evidence by scientific
authorities [29] and resulted significantly related to higher
VC also in our study.
Among recommended with strong evidence immuniza-
tion information systems, the digitized vaccine registries
could be considered. Even if they are active in all participating
LHUs, only about the half reported regional immunization
strategies, that resulted significantly related to higher VC.
This limits the sharing of immunization data between LHUs
and from LHUs to regional authorities, compromising the
governance of immunization policies.
Even though adverse events surveillance could not be
strictly considered an organizational aspect, we investigated
routine system used by LHUs to monitor adverse events as
relevant quality and safety standard of immunization policies.
Surprisingly, 30 minutes surveillance and regional vaccine-
vigilance systems are not conducted in all participating LHUs
and thus they should be extended and homogenised.
As regards communication strategies, almost all par-
ticipating LHUs reported education activities on universal
HPV immunization strategy targeting health care work-
ers. Education targets the main professionals involved in
HPV vaccine counselling but the proportions are low and
the interventions are conducted periodically only in the
half of LHUs, highlighting the need of promoting further
activities. This is of particular relevance in the field of
HPV primary and secondary prevention since a variety of
professionals operating in different healthcare settings are
involved along a decision path where the immunization
centre often represent the point of arrival. Furthermore,
available evidences demonstrate the importance of the role
of trusted healthcare provider in taking decisions in the field
of immunization [25, 26, 33, 40–42]. In particular, the HPV
vaccine targets preadolescents of both sexes and subjects at
risk; thus paediatricians and general practitioners ease the
link between subjects and immunization centre. Parents are
also involved in the decision path and they usually identify
gynaecologists as reference figure to obtain information on
a sexually transmitted infection causing anogenital cancers.
Subjects at risk could refer to infectious disease specialists and
oncologists but also dermatologists, urologists, and otolaryn-
gology specialists. Thus, the synergy between professionals
and their active role in vaccine offer are essential to obtain
a good compliance to HPV prevention strategies, including
vaccines.
Furthermore, sharing a unique and coherent message
among different stakeholders using available communication
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tools is crucial to obtain the best results in terms of adherence
to HPV vaccine. As healthcare planning activities should
include the phase of feedback and report, the discussion of
obtained VC and the analysis of vaccine hesitancy deter-
minants among healthcare workers were also investigated,
showing a prevalence as low as 57.7% and 34.6%, respectively.
The studied communications strategies directed to target
subjects included the availability of informative material
at immunization centres that was prepared by LHUs and
regions in 50% and 42.3%of cases, respectively, and translated
in other languages only in 19.2% of cases. Even if these factors
are not significantly related to VC, they could contribute
to the circulation of scientifically correct information and
compensate the spread of misleading messages by “no-vax”.
Furthermore, call centres coordinated by immunization cen-
tres to obtain information and address doubt about vaccines
are available in about the half of participating LHUs. The
involvement of media and the conduction of focus group in
particular in the school setting could increase the vaccine
demand by target when combined with other activities; nev-
ertheless, they are reported in less than half of participating
LHUs. This could be due to the suboptimal economic and
human resources currently available for prevention in the
majority of Italian regions.
Our findings are in line with the most recent evidences on
interventions aimed at improving HPV vaccine uptake [42–
46]. In particular, recall systems for missed administrations
and free access to vaccination centres resulted in the main
factors related to VC outcome in preadolescent girls, demon-
strating the importance of implementing the accessibility to
immunization services and the taking-care process of target
subjects by health care professionals.
Of concerns, no participating LHUs gained VC objectives
fixed by the Italian Ministry of Health, not only for the recent
target represented by preadolescent boys but also for themore
consolidated girls target. Furthermore, even if the PNPV
2017-2019 recommend the immunization of male who have
sex with men and some regions correctly included among
subjects at risk the HIV positive, the implementation of
specific strategies is largely suboptimal. These observations
are particularly serious from a public health perspective,
given the high prevalence of HPV infection and the variety
and burden of HPV-related diseases [1–4].
The strengths of our study are represented by the wide
spectrum of organizational aspects and communication tools
evaluated and the estimate of their role in determining
the best outcome in terms of VC. In Italy, from 2010 to
2013 the study “local and evaluation of HPV immunization
campaigns against HPV, VALORE” was coordinated by the
Ministry of Health and by the Istituto Superiore di Sanita`
in order to improve the compliance to HPV vaccine and
provide the regional and LHUs authorities the operational
tools to increase VC [47]. Various organizational aspects and
communications activities were investigated; nevertheless the
boys did not represent the target of HPV vaccine during the
study period and no multivariable analysis was conducted to
consider diverse independent variables simultaneously.
The main limitations of the study are the difficulty in
quantifying and exhaustively evaluating all organizational
aspects of immunization centres and communication strate-
gies and the number of participating LHUs that could
compromise the representativeness of the national picture.
Nevertheless, participating LHUs belong to four among the
most populous Italian regions, with heterogeneous sociode-
mographic characteristics and healthcare systems. In par-
ticular, school-based programs were not investigating, even
if robust evidences demonstrate their role in increasing the
compliance to HPV vaccine. Nevertheless, the paucity of
human resources in immunization centres reported in a wide
proportion of participating LHUs limits the feasibility of this
strategy.
5. Conclusions
In conclusion, our study demonstrated that the majority of
Italian LHUs implemented proved actions (e.g., active free
offer, invite letter, and recall of subjects who missed vac-
cine administration) concurrently with some HPV vaccine
promotion and communication strategies directed to target
subjects and healthcare workers. Nevertheless, VC observed
in participating LHUs are largely lower than the national
objectives in all HPV vaccine targets and organizational
strategies to reach subjects at risk are suboptimal.
Since multicomponent interventions have a synergistic
effect, both organizational and educational strategies have to
be implemented to improve HPV VC.
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